Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:40 PM
Ignite Modification Date:
2025-12-24 @ 10:40 PM
NCT ID:
NCT04015635
Brief Summary:
To define the cytokine and cellular immune signature of primary hypertension. Cross sectional clinical/laboratory study.
Detailed Description:
Experimental data show the presence of immune and inflammatory systems dysregulation in hypertension. Understanding of the inflammatory and immune nature of hypertension is currently based on studies in rodent models of hypertension, but is supported by human epidemiological and genome wide association studies (GWAS) studies. It is now essential to identify key checkpoints and inflammatory mechanism(s) involved in human hypertension in comprehensive and sufficiently powered studies, which will then be able to guide subsequent in-depth hypothesis-driven mechanistic studies. This approach may provide the basis for future randomized clinical trials (RCTs).
To define the relationships and predictive value of the immune signature of hypertension and clinical phenotypes of hypertension :
* Predictive value of immune signature for blood pressure parameters measured by ambulatory blood pressure measurements (ABPM)
* Predictive value of immune signature for endothelial function assessed by Endo-PAT2000 and flow mediated dilatation (FMD) both complementary non-invasive techniques.
* Predictive value of immune signature for vascular stiffness and central pressure assessed by SphygmoCor
* Predictive value of immune signature for renal function parameters
* Predictive value of immune signature for cognitive function. To define genetic determinants of immune signature of hypertension.
Study:
NCT04015635
Study Brief:
Protocol Section:
NCT04015635